A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Latest Information Update: 09 Nov 2024
At a glance
- Drugs Paclitaxel (Primary)
- Indications Head and neck cancer; Paranasal-sinus-neoplasms; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HNSCC
- Sponsors Fulgent Pharma
Most Recent Events
- 15 Apr 2024 Status changed from not yet recruiting to recruiting.
- 29 Mar 2024 Status changed from planning to not yet recruiting.
- 03 Nov 2023 According to Fulgent Genetics media release, the company expects to initiate this study in first quarter of 2024.